Introduction
Clozapine is an atypical antipsychotic used in the treatment of resistant schizophrenia with an established efficacy superior to other antipsychotics [Wahlbeck et al. 1999] . Clozapine is associated with a range of side effects including those which are rare and life-threatening such as cardiomyopathy [Hagg et al. 2000] , and others that are relatively common such as hypersalivation [Syed et al. 2008 ] and weight gain [Wirshing et al. 1999] . Discontinuation of clozapine is not uncommon in the first year [Ciapparelli et al. 2000] , with a large aim of this survey was to assess patient satisfaction with clozapine in comparison with previous antipsychotics and patients' experience of the side effects of clozapine treatment as well as its impact on subjective well-being.
Method
The survey was undertaken at a forensic psychiatric hospital in the north-west of England. All patients prescribed a stable dose of clozapine for a minimum of 3 months were approached to take part in the survey. Of the 67 patients approached, 84% of patients agreed to participate in the survey and data were collected by medical staff who were part of the patient's care team.
The survey sample consisted of 56 men, with a mean age of 37.9 years [standard deviation (SD): 10.6, range: 22-59 years). A total of 42 respondents were White British, while the remainder included: 3 Other White; 3 White or Black Caribbean; 2 Black Caribbean; 2 Black African; 2 Pakistani; 1 Black or White African; and 1 Other Asian Background. The mean daily dose of clozapine was 349.3 mg (SD: 134.0 mg, range: 125-850 mg) and the mean length of prescription was 520.1 days (range: 93-2074 days).
A 27-item questionnaire was used to assess subjective experiences with items adapted from a North American survey [Waserman and Criollo, 2000] . Respondents were asked to rate side effects and satisfaction with clozapine in comparison to previously prescribed antipsychotic medication on a five-point scale (much worse, worse, no different, better, much better). We also asked respondents to rate the effects experienced in terms of hedonic response (how they felt about them) on a five-point scale (very unhappy about it, unhappy about it, don't mind either way, happy about it, very happy about it).
All data were gathered in accordance with the service evaluation standards of the responsible institutional review board (Research Governance Committee, Mersey Care NHS Trust).
Results
Respondents were largely positive about clozapine treatment: 86% of respondents reported that treatment with clozapine was better than treatment with previous antipsychotics and none thought it worse; 89% of respondents reported greater satisfaction with clozapine; and 96% reported better compliance with clozapine treatment than with previously prescribed antipsychotics.
Ratings of changes in side effects as a result of clozapine treatment are shown in Table 1 . Responses revealed the most positive effects with clozapine treatment were in the domains of quality of life (mean: 3.93) and social abilities (mean: 3.59); 68% of patients (n = 38) reported their quality of life had improved and 52% of patients (n = 29) reported an improvement in their social abilities. A total of 46% of respondents (n = 26) reported improvements in 'thinking' (a marker for cognitive ability) since starting clozapine treatment but 13% (n = 7) reported a deterioration in 'thinking'. Similarly, 48% (n = 27) reported improvements in sleep but 20% (n = 11) reported worse sleep than before. An improvement in mood was reported by 43% (n = 24) of the patients.
Nocturnal hypersalivation was overwhelmingly the most frequently reported negative side effect, reported by 84% of patients (n = 47) (mean: 1.72); 57% of the patients (n = 32) also reported weight gain (mean: 2.29), 41% (n = 23) reported deterioration in daytime salivation and 39% reported an increase in constipation (n = 22). In addition, 27% of patients also reported a worsening of thirst (n = 15).
To assess the subjective experience of effects associated with clozapine, hedonic responses were grouped into those patients for whom the effect had improved and those for whom it had deteriorated. The hedonic ratings were then averaged for each of the two groups. To maintain reliability of the ratings, only groups that included at least 20% of patients were included (see Table 2 ). Whilst many side effects deteriorated for many patients, the hedonic impact of this deterioration varied. For example, patients disliked the change in weight (mean hedonic rating: 1.81) more than they disliked the change in appetite (mean hedonic rating: 2.18). However, the most adverse impact on subjective well-being by far was deterioration in nocturnal salivation (mean hedonic rating: 1.72).
Effects that improved as a result of clozapine treatment included a range of responses. For example, when patients perceived an improvement in quality of life, they reported being slightly happier about this (mean hedonic rating: 4.37) Table 1 . Subjective experiences of side effects: ratings of clozapine treatment compared with previous antipsychotic treatment (n = 56).
Number of responses
Mean rating
After starting clozapine, did the following change? Note: Change ratings were on a 5-point scale where 1 = 'much worse than before' and 5 = 'much better than before'. 
Discussion
We could not find any previous published survey that sought to explore the effects and overall satisfaction with clozapine and the relative significance of effects experienced, both positive and adverse, in terms of impact on subjective wellbeing. In this survey in a UK forensic mental health service, 86% of the respondents reported treatment with clozapine as very positive in comparison with previous medication and 68% of the patients reported improved quality of life.
These are important findings for clinicians within a forensic setting, particularly where there has been a delay in commencing clozapine [Howes et al. 2012] and our findings are similar to a survey in a non-forensic sample [Taylor et al. 2000 ]. In our survey, nocturnal hypersalivation was the most commonly experienced adverse effect and this is consistent with a previous survey of the prevalence of adverse effects in North America [Waserman and Criollo, 2000 ].
The added contribution that our survey makes is in asking respondents about the associated significance attached to each side effect; responses indicated clear differences in terms of impact on subjective well-being. For example, nocturnal hypersalivation was the most distressing side effect experienced by our sample of patients followed by weight gain. In terms of positive effects when patients perceived an improvement in quality of life, they reported being slightly happier about this than about the improvement in energy levels. Patients also attributed a large subjective significance to improvement in mood.
Patients' subjective experiences of medication are important and it is recognized that these are powerful predictors of adherence [Fujikawa et al. 2008] , which in turn influences treatment outcomes [Hellewell, 2002] . However, many patients with a diagnosis of schizophrenia discontinue their medication in the first few years, citing their experience of side effects as a crucial aspect of their decision [Kampman and Lehtinen, 1999] . We suggest that clinicians should be aware of the relative impact of different side effects. Several instruments have been developed to evaluate perceived side effects of antipsychotic treatment: Medication and Adherence Rating Scale [Thompson et al. 2000 ]; Self-rating Scale to Measure Subjective Well-being under Neuroleptic Treatment [Naber, 1995] ; and Patient Assessment Questionnaire [Mojtabai et al. 2012 ]. We are not aware of these being used in routine clinical practice and it might be worth exploring the use of such instruments whilst patients wait in clozapine clinics and the responses discussed at subsequent clinical reviews.
This was a survey of patients established on clozapine therapy with a minimum duration of treatment of 93 days and mean duration of 520 days, indicating the sample is positively biased in favour of clozapine therapy. Additionally, the relatively small number of respondents in this survey may not be representative of patients in other forensic services. However, we had an encouraging response rate and our population of a broad ethnic mix of patients, although exclusively male, is unlikely to be significantly different from other male forensic populations.
In conclusion, clinicians should routinely explore not only the presence of effects of clozapine treatment, both positive and negative, but also their subjective importance in terms of impact on well-being. This may provide an opportunity to highlight the positive changes and to prioritize management of the most undesirable adverse effects, which is likely to promote adherence to medications and improve longer term treatment outcomes.
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